Completed PHASE3 INTERVENTIONAL NCT00212719

Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in Japan

Sponsor: Ono Pharmaceutical Co. Ltd

Interventions ONO-5920

Updated 5 times since 2017 Last updated: Oct 10, 2012 Started: May 31, 2003 Primary completion: Apr 30, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Involutional Osteoporosis, this trial is completed. The trial is conducted by Ono Pharmaceutical Co. Ltd and has accumulated 5 data snapshots since 2003. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

May 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ono Pharmaceutical Co. Ltd

Data source: Ono Pharmaceutical Co. Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.